✦ LIBER ✦

Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET

✍ Scribed by Janjigian, Y. Y.; Viola-Villegas, N.; Holland, J. P.; Divilov, V.; Carlin, S. D.; Gomes-DaGama, E. M.; Chiosis, G.; Carbonetti, G.; de Stanchina, E.; Lewis, J. S.

Book ID: 120179358
Publisher: The Society of Nuclear Medicine
Year: 2013
Tongue: English
Weight: 783 KB
Volume: 54
Category: Article
ISSN: 0161-5505
DOI: 10.2967/jnumed.112.110239

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biodistribution of 89Zr-trastuzumab and

Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

✍ Dijkers, E C; Oude Munnink, T H; Kosterink, J G; Brouwers, A H; Jager, P L; de J 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 309 KB

18F-FDG PET/CT for Early Prediction of R

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

✍ Kenny, L. M. 📂 Article 📅 2013 🏛 The Society of Nuclear Medicine 🌐 English ⚖ 51 KB

18F-FDG PET/CT for Early Prediction of R

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

✍ Gebhart, G.; Gamez, C.; Holmes, E.; Robles, J.; Garcia, C.; Cortes, M.; de Azamb 📂 Article 📅 2013 🏛 The Society of Nuclear Medicine 🌐 English ⚖ 330 KB